newsfilter
← Latest News
Business Wire·

GlycoMimetics Announces Strategic Review and Corporate Restructuring Plan

After meeting with the U.S. Food and Drug Administration (FDA), it has been determined that the regulatory path forward for uproleselan in relapsed and refractory (R/R) Acute Myeloid Leukemia (AML) would require an